• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    8/17/23 5:32:21 PM ET
    $ATHX
    $AVTX
    $BBLG
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHX alert in real time by email

    Gainers

    • TRACON Pharma (NASDAQ:TCON) stock moved upwards by 26.8% to $0.26 during Thursday's after-market session. The market value of their outstanding shares is at $6.8 million. As per the press release, Q2 earnings came out 3 days ago.
    • Alpha Tau Medical (NASDAQ:DRTS) shares increased by 23.61% to $4.45. Alpha Tau Medical's trading volume hit 52.6K shares by close, accounting for 114.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $308.2 million.
    • Avalo Therapeutics (NASDAQ:AVTX) shares increased by 23.12% to $0.18. Avalo Therapeutics's trading volume hit 8.3 million shares by close, accounting for 376.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.6 million.
    • Neoleukin Therapeutics (NASDAQ:NLTX) shares rose 13.25% to $0.82. This security traded at a volume of 174.4K shares come close, making up 67.1% of its average volume over the last 100 days. The company's market cap stands at $36.0 million.
    • GRI Bio (NASDAQ:GRI) stock increased by 13.2% to $2.88. The market value of their outstanding shares is at $8.3 million. The company's, Q2 earnings came out 3 days ago.
    • Assure Hldgs (NASDAQ:IONM) stock rose 9.51% to $0.34. The company's market cap stands at $1.8 million. As per the news, the Q2 earnings report came out 3 days ago.

    Losers

    • Athersys (NASDAQ:ATHX) shares fell 13.8% to $0.34 during Thursday's after-market session. This security traded at a volume of 63.4K shares come close, making up 28.0% of its average volume over the last 100 days. The company's market cap stands at $6.9 million. As per the press release, Q2 earnings came out yesterday.
    • Incannex Healthcare (NASDAQ:IXHL) stock decreased by 12.41% to $1.26. The market value of their outstanding shares is at $80.0 million.
    • Bone Biologics (NASDAQ:BBLG) shares fell 10.67% to $0.88. The company's market cap stands at $2.7 million.
    • Renovaro Biosciences (NASDAQ:RENB) shares decreased by 8.03% to $1.49. At the close, Renovaro Biosciences's trading volume reached 199.4K shares. This is 3.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $94.9 million.
    • Cingulate (NASDAQ:CING) shares decreased by 7.53% to $0.58. The market value of their outstanding shares is at $8.0 million. As per the news, the Q2 earnings report came out 3 days ago.
    • VolitionRX (AMEX:VNRX) shares decreased by 6.93% to $1.21. The company's market cap stands at $94.5 million. As per the news, the Q2 earnings report came out 3 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATHX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHX
    $AVTX
    $BBLG
    $CING

    CompanyDatePrice TargetRatingAnalyst
    Alpha Tau Medical Ltd.
    $DRTS
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Avalo Therapeutics Inc.
    $AVTX
    8/15/2025Overweight
    Cantor Fitzgerald
    Avalo Therapeutics Inc.
    $AVTX
    6/2/2025$15.00Buy
    H.C. Wainwright
    VolitionRX Limited
    $VNRX
    4/8/2025$2.50Buy
    H.C. Wainwright
    More analyst ratings

    $ATHX
    $AVTX
    $BBLG
    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    $AVTX
    $BBLG
    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alpha Tau downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Alpha Tau from Overweight to Neutral and set a new price target of $5.00

    3/4/26 8:30:52 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    $AVTX
    $BBLG
    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rootsaert Rodney Gerard

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/19/26 4:30:28 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Forterre Gael

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/19/26 4:30:29 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Micallef Jacob Vincent

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    3/19/26 4:30:18 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ATHX
    $AVTX
    $BBLG
    $CING
    SEC Filings

    View All

    Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

    3/27/26 4:01:28 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Cingulate Inc.

    424B3 - Cingulate Inc. (0001862150) (Filer)

    3/27/26 4:01:35 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Incannex Healthcare Inc. (0001873875) (Filer)

    3/27/26 8:00:23 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHX
    $AVTX
    $BBLG
    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position

    MELBOURNE, Australia and NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has reactivated its previously approved share repurchase program, with the program having been active over the past two trading days. The Company has utilized the buyback program opportunistically in the past, however had not actively repurchased shares in recent periods. The decision to reinitiate buyback activity reflects the Board of Directors' view that the Company's current market valuation does not accurately reflect the strength of its balance sheet, clinical prog

    3/27/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

    HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients. Poster 244P : Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation1Joint lead author Dr. Pei-Hsing Chen, Assistant Professor, Surgical Department, National Taiwan University Hospital, Taipei City, Taiwan, said:"A key finding from this study was that measuring preoperative H3K27Me3-nucleos

    3/26/26 8:17:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

    Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference CallDate:  Wednesday, April 1, 2026Time:  8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (t

    3/25/26 4:12:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ATHX
    $AVTX
    $BBLG
    $CING
    Leadership Updates

    Live Leadership Updates

    View All

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

    HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026.Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal diseas

    1/20/26 8:25:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ATHX
    $AVTX
    $BBLG
    $CING
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    $ATHX
    $AVTX
    $BBLG
    $CING
    Financials

    Live finance-specific insights

    View All

    VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

    Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference CallDate:  Wednesday, April 1, 2026Time:  8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (t

    3/25/26 4:12:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Third Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, November 14, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800

    11/10/25 8:45:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care